Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Identifying DNA Biomarkers of Bacillus Calmette-Guerin (BCG) Resistance in Non-Muscle-Invasive Bladder Cancer

Funder: Canadian Institutes of Health Research

Funding period
CAD 1 K
USD 847
Funding amount
Abstract
In 2017, bladder cancer was the fifth most common cancer in North America, with non-muscle-invasive bladder cancer (NMIBC) making up nearly 80% of all new cases. These patients are treated with Bacillus Calmette-Guerin (BCG) and typically have favourable long-term survival odds. Unfortunately, bladder tumours are highly prone to recurrence and some will progress to a more aggressive and invasive form after treatment. Up to 60% of patients who receive BCG will see their tumour recur within 2 years and up to half of these will progress, though the mechanism of resistance remains unknown. To study this phenomenon, we have collaborated with an international team of clinicians to collect patient tumour samples from before and after BCG therapy. We subsequently used DNA sequencing to compare the genetic changes between the pre- and post- samples to understand how the tumours responded to treatment. The aim of this research is to find specific indicators that differentiate the patients that respond positively to BCG from those who show resistance, thereby enabling clinicians to personalise therapy to individual patients. We have sequenced 20 patients and identified a number of potential indicators that predict successful outcomes on BCG therapy. This work represents the first time a cohort of NMIBC patients have been genetically profiled both pre- and post- BCG. In light of these findings, we have secured samples from a further 95 patients to continue exploring these trends. Our goal is to identify specific, reproducible indicators that can help guide treatment decisions in the clinic.
Similar projects All >
Sorted by: Start Date
Project list item
Targeting FGF in Bladder cancer after Neoadjuvant Immunotherapy and Surgery

American Association For Cancer Research to Joshua James Meeks

USD 25,000
2019 - 2020
Project list item
Biomarker-Based Tools for Treatment Response Decision Support of Bladder Cancer

National Cancer Institute to LUBOMIR M HADJIYSKI, AJJAI SHIVARAM ALVA

USD 653,319
2019 - 2024
Project list item
Refined phenotyping and personalized targeting of muscle-invasive bladder cancer

Swiss National Science Foundation to Roland Seiler, Vera Genitsch, Kiu Yan Charlotte Ng, Marianna Kruithof-de Julio, Franziska Singer

USD 702,564
2019 - 2023
Project list item
Chromatin Modifier Gene Mutation and Enhancer Dysfunction in Bladder Cancer

National Cancer Institute to BYRON H LEE

USD 243,205
2019 - 2024

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science